Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
HER2 targeted therapies have significantly improved prognosis of HER2-positive breast and gastric cancer. HER2 overexpression and mutation is the pathogenic driver in non-small cell lung cancer (NSCLC) and colorectal cancer, however, to date, there are no approved HER2-targeted therapies with these...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125530/ https://www.ncbi.nlm.nih.gov/pubmed/33946310 http://dx.doi.org/10.3390/ijms22094774 |